Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads

Transplantation

Volumn 87, Issue 11, 2009, Pages 1681-1688

  Amico, Patrizia ^a   Hönger, Gideon ^a   Mayr, Michael ^a   Steiger, Jürg ^a   Hopfer, Helmut ^b   Schaub, Stefan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antibody mediated rejection; Flow cytometry; HLA antibodies; Solid phase assays

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; DACLIZUMAB; HLA ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ANALYTIC METHOD; ANTIBODY DETECTION; ANTIBODY MEDIATED REJECTION; ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PREDICTIVE VALIDITY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE ANTIGEN FLOW BEAD;

ADOLESCENT; ADULT; AGED; BIOPSY; CADAVER; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PREOPERATIVE CARE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TISSUE DONORS; YOUNG ADULT;

EID: 67649586593     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a5e034     Document Type: Article

References (25)

1. Bielmann D, Honger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant 2007; 7: 626.
2. Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies. Transplantation 2008; 85: 1557.
3. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The Emory algorithm. Am J Transplant 2006; 6: 2307.
4. Patel AM, Pancoska C, Mulgaonkar S, et al. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007; 7: 2371.
5. Gupta A, Iveson V, Varagunam M, et al. Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? Transplantation 2008; 85: 1200.
6. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85: 1086.
7. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.AmJ Transplant 2006; 6: 346.
8. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008; 8: 324.
9. Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: Diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242.
10. Seemayer CA, Gaspert A, Nickeleit V, et al. C4d staining of renal allograft biopsies: A comparative analysis of different staining techniques. Nephrol Dial Transplant 2007; 22: 568.
11. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
12. Klitz W, Maiers M, Spellman S, et al. New HLA haplotype frequency reference standards: High-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. Tissue Antigens 2003; 62: 296.
13. El-Awar NR, Akaza T, Terasaki PI, et al. Human leukocyte antigen class I epitopes: Update to 103 total epitopes, including the C locus. Transplantation 2007; 84: 532.
14. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684.
15. Karuppan SS, Ohlman S, Moller E. The occurrence of cytotoxic and non-complement-fixing antibodies in the crossmatch serum of patients with early acute rejection episodes. Transplantation 1992; 54: 839.
16. Eng HS, Bennett G, Tsiopelas E, et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predict late graft loss. Am J Transplant 2008; 8: 2335.
17. Duquesnoy RJ. A structurally based approach to determine HLA compatibility at the humoral immune level. Hum Immunol 2006; 67: 847.
18. Duquesnoy RJ, Awadalla Y, Lomago J, et al. Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes. Transpl Immunol 2008; 18: 352.
19. Salama AD, Delikouras A, Pusey CD, et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260.
20. Jindra PT, Hsueh A, Hong L, et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol 2008; 180: 2214.
21. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046.
22. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation.NEngl JMed 2007; 357: 2562.
23. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donorHLAclass II.AmJ Transplant 2007; 7: 857.
24. Bray RA, Nickerson PW, Kerman RH, et al. Evolution of HLA antibody detection: Technology emulating biology. Immunol Res 2004; 29: 41.
25. Gebel HM, Harris SB, Zibari G, et al. Conundrums with FlowPRA beads. Clin Transplant 2002; 16(suppl 7): 24.